{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:05:16Z","timestamp":1773389116253,"version":"3.50.1"},"reference-count":32,"publisher":"Jaypee Brothers Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.59556\/japi.74.1425","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:10:44Z","timestamp":1773378644000},"page":"46-50","source":"Crossref","is-referenced-by-count":0,"title":["Implications of Acetylator Status and Therapeutic Drug Monitoring of Plasma Rifampicin and Isoniazid Concentrations among Indians"],"prefix":"10.59556","volume":"74","author":[{"given":"Prerna R","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan V","family":"Lokhande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad R","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpa J","family":"Dherai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarir F","family":"Udwadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lancelot","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Sunavala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Soman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jignesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tester F","family":"Ashavaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20260313051035_B1","volume-title":"Global tuberculosis report 2022.","year":"2022."},{"issue":"(1):","key":"key20260313051035_B2","article-title":"The role of therapeutic drug monitoring in mycobacterial infections.","volume":"5","author":"Peloquin","year":"2017;","journal-title":"Microbiol Spectr"},{"issue":"(10):","key":"key20260313051035_B3","doi-asserted-by":"crossref","first-page":"1546\u2013","DOI":"10.3201\/eid1610.100374","article-title":"Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.","volume":"16","author":"Heysell","year":"2010;","journal-title":"Emerg Infect Dis"},{"issue":"(11):","key":"key20260313051035_B4","doi-asserted-by":"crossref","first-page":"1442\u2013","DOI":"10.5588\/ijtld.12.0771","article-title":"Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.","volume":"17","author":"Babal\u0131k","year":"2013;","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(1):","key":"key20260313051035_B5","first-page":"118.","article-title":"N-acetyltransferase gene polymorphisms and plasma isoniazid concentrations in patients with tuberculosis.","volume":"145","author":"Ramachandran","year":"2017;","journal-title":"Indian J Med Res"},{"issue":"(5):","key":"key20260313051035_B6","doi-asserted-by":"crossref","first-page":"1178\u2013","DOI":"10.1378\/chest.113.5.1178","article-title":"Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.","volume":"113","author":"Kimerling","year":"1998;","journal-title":"Chest"},{"key":"key20260313051035_B7","article-title":"Drug susceptibility in the chemotherapy of mycobacterial infections.","author":"Heifets","year":"2019.","journal-title":"CRC Press;"},{"issue":"(3):","key":"key20260313051035_B8","doi-asserted-by":"crossref","first-page":"1215.","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells.","volume":"16","author":"Miller","year":"1988;","journal-title":"Nucleic Acids Res"},{"issue":"(1):","key":"key20260313051035_B9","first-page":"29.","article-title":"High performance liquid chromatographic quantification of rifampicin in human plasma: method for therapeutic drug monitoring.","volume":"56","author":"Sameh","year":"2013;","journal-title":"Pak J Sci Indus Res"},{"issue":"(1):","key":"key20260313051035_B10","doi-asserted-by":"crossref","first-page":"13\u2013","DOI":"10.3126\/saarctb.v9i1.6960","article-title":"Simple and rapid liquid chromatography method for simultaneous determination of isoniazid and pyrazinamide in plasma.","volume":"9","author":"Hemanth","year":"2012;","journal-title":"SAARC J Tuberc Lung Dis"},{"key":"key20260313051035_B11","article-title":"Guidance for Industry: Bioanalytical Method Validation.","author":"Center for Drug Evaluation and Research; Center for Veterinary Medicine. US Food and Drug Administration.","year":"2018.","journal-title":"Center for Drug Evaluation and Research;"},{"issue":"(9):","key":"key20260313051035_B12","doi-asserted-by":"crossref","first-page":"1185\u2013","DOI":"10.1093\/bioinformatics\/btp121","article-title":"A web-server for inferring the human N acetyltransferase 2 NAT2 enzymatic phenotype from NAT2 genotype.","volume":"25","author":"Kuznetsov","year":"2009;","journal-title":"Bioinformatics"},{"key":"key20260313051035_B13","first-page":"1\u2013","article-title":"Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA.","volume":"2013:","author":"Heysell","year":"2013;","journal-title":"Tuberc Res Treat"},{"issue":"(7):","key":"key20260313051035_B14","doi-asserted-by":"crossref","first-page":"552\u2013","DOI":"10.1080\/23744235.2017.1292542","article-title":"Failure to reach therapeutic levels of rifampicin and isoniazid by recommended dosages.","volume":"49","author":"Chawla","year":"2017;","journal-title":"Infect Dis (Lond)"},{"issue":"(12):","key":"key20260313051035_B15","doi-asserted-by":"crossref","first-page":"1602\u2013","DOI":"10.5588\/ijtld.13.0019","article-title":"Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.","volume":"17","author":"Fahimi","year":"2013;","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(9):","key":"key20260313051035_B16","doi-asserted-by":"crossref","first-page":"1464\u2013","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes.","volume":"208","author":"Pasipanodya","year":"2013;","journal-title":"J Infect Dis"},{"issue":"(6):","key":"key20260313051035_B17","doi-asserted-by":"crossref","first-page":"497\u2013","DOI":"10.5588\/09640569513002","article-title":"Low plasma concentrations of rifampicin in tuberculosis patients in Indonesia.","volume":"6","author":"Van Crevel","year":"2002;","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(9):","key":"key20260313051035_B18","first-page":"972\u2013","article-title":"Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.","volume":"11","author":"Um","year":"2007;","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(17):","key":"key20260313051035_B19","doi-asserted-by":"crossref","first-page":"2035\u2013","DOI":"10.5897\/AJPP11.511","article-title":"Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations.","volume":"5","author":"Kayhan","year":"2011;","journal-title":"Afr J Pharm Pharmacol"},{"issue":"(7):","key":"key20260313051035_B20","doi-asserted-by":"crossref","first-page":"3208\u2013","DOI":"10.1128\/AAC.02599-12","article-title":"Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.","volume":"57","author":"Tostmann","year":"2013;","journal-title":"Antimicrob Agents Chemother"},{"issue":"(5):","key":"key20260313051035_B21","doi-asserted-by":"crossref","first-page":"1520\u2013","DOI":"10.1378\/chest.120.5.1520","article-title":"Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy.","volume":"120","author":"Mehta","year":"2001;","journal-title":"Chest"},{"issue":"(2):","key":"key20260313051035_B22","doi-asserted-by":"crossref","first-page":"221\u2013","DOI":"10.5588\/ijtld.12.0279","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis.","volume":"17","author":"Van Tongeren","year":"2013;","journal-title":"Int J Tuberc Lung Dis"},{"issue":"(4):","key":"key20260313051035_B23","doi-asserted-by":"crossref","first-page":"461\u2013","DOI":"10.1086\/431984","article-title":"Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.","volume":"41","author":"Tappero","year":"2005;","journal-title":"Clin Infect Dis"},{"key":"key20260313051035_B24","first-page":"89\u2013","article-title":"Role of pharmacogenomics in the treatment of tuberculosis: a review.","volume":"5:","author":"Ramachandran","year":"2012;","journal-title":"Pharmgenomics Pers Med"},{"key":"key20260313051035_B25","doi-asserted-by":"crossref","first-page":"853602.","DOI":"10.1155\/2013\/853602","article-title":"Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients.","volume":"2013:","author":"Zabost","year":"2013;","journal-title":"Biomed Res Int"},{"issue":"(6):","key":"key20260313051035_B26","doi-asserted-by":"crossref","first-page":"716\u2013","DOI":"10.1590\/S0074-02762011000600011","article-title":"Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.","volume":"106","author":"Teixeira","year":"2011;","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"(10):","key":"key20260313051035_B27","doi-asserted-by":"crossref","first-page":"1403\u2013","DOI":"10.5588\/ijtld.10.0648","article-title":"N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.","volume":"15","author":"Leiro-Fernandez","year":"2011;","journal-title":"Int J Tuberc Lung Dis"},{"key":"key20260313051035_B28","doi-asserted-by":"crossref","first-page":"8765347.","DOI":"10.1155\/2020\/8765347","article-title":"Study on genotyping polymorphism and sequencing of N-acetyltransferase 2(NAT2) among Al-Ahsa population.","volume":"2020:","author":"Zahra","year":"2020;","journal-title":"Biomed Res Int"},{"issue":"(8):","key":"key20260313051035_B29","first-page":"68\u2013","article-title":"Importance of therapeutic drug monitoring of rifampicin.","volume":"64","author":"Chawla","year":"2016;","journal-title":"J Assoc Physicians India"},{"issue":"(11):","key":"key20260313051035_B30","doi-asserted-by":"crossref","first-page":"491\u2013","DOI":"10.1211\/146080800128735575","article-title":"Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions.","volume":"6","author":"Singh","year":"2000;","journal-title":"Pharm Pharmacol Commun"},{"issue":"(3):","key":"key20260313051035_B31","doi-asserted-by":"crossref","first-page":"234.","DOI":"10.3390\/pharmaceutics12030234","article-title":"Improved stability of rifampicin in the presence of gastric-resistant isoniazid microspheres in acidic media.","volume":"12","author":"Mwila","year":"2020;","journal-title":"Pharmaceutics"},{"issue":"(2):","key":"key20260313051035_B32","first-page":"56\u2013","article-title":"Drug interactions with tuberculosis therapy: main topic. CME: Your SA Journal of CPD","volume":"23","author":"Swart","year":"2005;"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:10:48Z","timestamp":1773378648000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-3-46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.59556\/japi.74.1425"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1425","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}